BCM

Houston, TX, United States
Houston, TX, United States

Time filter

Source Type

News Article | May 11, 2017
Site: www.prnewswire.com

The OTC 2017 featured a special procurement seminar on Ukraine organized by the U.S. Commercial Service in Ukraine, with support from Burisma Group. The event brought together representatives of Ukrainian and foreign oil & gas producers, embassies, NGOs and industry experts to address Ukraine's gas market future, business challenges and opportunities. Among key speakers at the seminar were the Senior Commercial Officer of the U.S. Commercial Service in Ukraine Jim Lindley, the Senior Oil and Gas Sector Specialist Myroslava Myrtsalo, the CEO of Ukrgazvydobuvannia Oleg Prokhorenko and the Advisor to the Board of Directors at Burisma Group Vadym Pozharskyi. In his address entitled 'Private gas production as a key to ensuring national energy security and independence', Vadym Pozharskyi, Advisor to the Board of the Burisma Group, focused on the need to boost Ukraine's domestic gas production. He talked about new ways to increase gas output, the importance of cooperation with the public sector and Burisma's state-of-the-art technology and oil and gas services. "Based on our 2017 corporate program, we will be investing circa UAH 3 billion in exploration and production. We are proud to produce billions of cubic meters of gas and contribute billions of hryvnias to the state budget of Ukraine. The huge advantage of the OTC for Ukraine is that it offers latest technologies allowing us to ramp up Ukraine's domestic gas production," Vadym Pozharskyi explained. The address also discussed how Ukraine offers an attractive investment environment and growth opportunities to oil and gas and service companies. It also recognised the effort and progress the country has made. In May, Burisma Group will be introducing the largest drilling rig in Ukraine. Vadym Pozharskyi extended an invitation to all participants of the OTC 2017 seminar on Ukraine to attend the event. For more detailed information please contact our press-centre: media@burisma.com Founded in 1969, the OTC is one of the key oil and gas industry events focused on offshore exploration, drilling and production. The NRG Park hosted over 2,300 companies from 100 countries that brought their projects and technologies. This year, the tradeshow attracted a record number of attendees - over 90,000 traders, managers, businessmen, engineers and scientists. The OTC is ranked among 200 largest tradeshows held annually in the United States and is among 10 largest gatherings in terms of attendance. Burisma Group is an independent oil and gas company operating in Ukraine. Since its launch in 2002, the Company has rapidly become one of the largest independent gas producers in the country. Burisma has been engaged in oil and gas exploration and production for more than 10 years. The core business is located in Ukraine, where the Group is the largest independent natural gas producer. Burisma is a market leader with annualized natural gas production circa 1,1 BCM and over 30% market share. Burisma is seeking for opportunities to expand its portfolio to other countries. Burisma has a state-of-the-art equipment and many years of experience to provide best services for oil and gas companies around the world. For more information, please visit http://burisma.com/en/


News Article | May 11, 2017
Site: www.prnewswire.co.uk

The OTC 2017 featured a special procurement seminar on Ukraine organized by the U.S. Commercial Service in Ukraine, with support from Burisma Group. The event brought together representatives of Ukrainian and foreign oil & gas producers, embassies, NGOs and industry experts to address Ukraine's gas market future, business challenges and opportunities. Among key speakers at the seminar were the Senior Commercial Officer of the U.S. Commercial Service in Ukraine Jim Lindley, the Senior Oil and Gas Sector Specialist Myroslava Myrtsalo, the CEO of Ukrgazvydobuvannia Oleg Prokhorenko and the Advisor to the Board of Directors at Burisma Group Vadym Pozharskyi. In his address entitled 'Private gas production as a key to ensuring national energy security and independence', Vadym Pozharskyi, Advisor to the Board of the Burisma Group, focused on the need to boost Ukraine's domestic gas production. He talked about new ways to increase gas output, the importance of cooperation with the public sector and Burisma's state-of-the-art technology and oil and gas services. "Based on our 2017 corporate program, we will be investing circa UAH 3 billion in exploration and production. We are proud to produce billions of cubic meters of gas and contribute billions of hryvnias to the state budget of Ukraine. The huge advantage of the OTC for Ukraine is that it offers latest technologies allowing us to ramp up Ukraine's domestic gas production," Vadym Pozharskyi explained. The address also discussed how Ukraine offers an attractive investment environment and growth opportunities to oil and gas and service companies. It also recognised the effort and progress the country has made. In May, Burisma Group will be introducing the largest drilling rig in Ukraine. Vadym Pozharskyi extended an invitation to all participants of the OTC 2017 seminar on Ukraine to attend the event. For more detailed information please contact our press-centre: media@burisma.com Founded in 1969, the OTC is one of the key oil and gas industry events focused on offshore exploration, drilling and production. The NRG Park hosted over 2,300 companies from 100 countries that brought their projects and technologies. This year, the tradeshow attracted a record number of attendees - over 90,000 traders, managers, businessmen, engineers and scientists. The OTC is ranked among 200 largest tradeshows held annually in the United States and is among 10 largest gatherings in terms of attendance. Burisma Group is an independent oil and gas company operating in Ukraine. Since its launch in 2002, the Company has rapidly become one of the largest independent gas producers in the country. Burisma has been engaged in oil and gas exploration and production for more than 10 years. The core business is located in Ukraine, where the Group is the largest independent natural gas producer. Burisma is a market leader with annualized natural gas production circa 1,1 BCM and over 30% market share. Burisma is seeking for opportunities to expand its portfolio to other countries. Burisma has a state-of-the-art equipment and many years of experience to provide best services for oil and gas companies around the world. For more information, please visit http://burisma.com/en/


News Article | May 29, 2017
Site: www.prnewswire.com

Group revenues for the first quarter in 2017 totaled NIS 1.5 billion compared with NIS 1.3 billion in the same period last year. The reason for the higher level of revenue in the current quarter was the increased E&P activities and contribution of Delek Israel. Group operating profit in the first quarter of 2017 totaled NIS 338 million, compared with NIS 277 million as reported in the same period last year. The increase was mainly due to higher sales of natural gas from the Tamar reservoir. Net income for the first quarter of 2017 totaled NIS 220 million compared with NIS 85 million in the first quarter of 2016. The E&P segment contributed a record of NIS 127 million to the Company's net income in the first quarter. Cash balance at the Delek Group as of May 28, 2017, stood at NIS 1.5 billion, including unutilized credit lines. It is noted that on February 22, 2017, Delek Group completed a successful debentures issuance through an expansion of Series B31, contributing NIS 1.0 billion to the balance sheet. Mr. Asaf Bartfeld, President and CEO of Delek Group, commented, "We have started off 2017 with strong financial results, and during the quarter we successfully completed a series of important strategic steps. Having acquired control of Ithaca, we intend to continue to strengthen the Group's international presence as part of our strategy to focus on the energy sector and become a key player in global markets". Tamar Project, 11 TCF natural gas discoveries (Tamar and Tamar SW). Tamar produced 2.4 BCM (~0.93 Bcf/d) of natural gas in the first quarter of 2017, an increase of 9% compared with 2.2 BCM (~0.85 Bcf/d) in the same period last year. In addition, Tamar sold 114 thousand barrels of condensate in the quarter, compared with 104 thousand barrels in the same period last year. Delek Group's (WI 17.68% of Tamar) average production for the quarter amounted to ~30.7k Boe/d. Tamar-8 development and production well: The drilling that began in October 2016 was completed in April 2017, including the completion of its connection to the production system. Tamar Sale Process: As per the Natural Gas Outline Plan, with regard to the Tamar sale to a third party, Delek Group's partnership, Delek Drilling (the new merged entity), announced that it intends to set up a Special Purpose Corporation. Through this, it will sell up to 10% of its rights in the Tamar and Dalit fields (out of 100% WI), located in the areas of leases I/12 Tamar and I/13 Dalit, respectively. This is subject to obtaining all the authorizations required in law as well as the various approvals and permits, and suitable market conditions. There can be no certainty that these conditions will all occur. According to the sale plan, the Special Purpose Corporation will offer securities to the public (equity and debentures) that will be registered for trading on the Tel Aviv Stock Exchange, and the Special Purpose Corporation will use the funds raised from the offering to purchase the rights in the fields that are sold by the Partnership. The profits from the above-mentioned sale, and profit from future sales of all the Partnership's holdings in the fields, are expected to be mainly used by the Partnership to distribute profits (including the distribution of advance tax payments), and for early repayment of debentures. In parallel to advancing the offering, the Partnership is continuing to assess various alternatives for the sale of the balance of its holdings in the fields. Leviathan, a 22 TCF natural gas discovery. On February 20, 2017, the Delek Group partnership signed a USD 1.75 billion limited recourse project financing agreement with a banking consortium for the development of Leviathan.  On February 23, 2017, an FID for Phase 1A of the development plan for the Leviathan Reservoir was sanctioned, with capacity of 12 BCM per year (~1.2 Bcf/d), and budget of USD 3.75 billion (at 100% WI), targeting first gas by the end of 2019. In April 2017, the Atwood Advantage drilling rig moved from Tamar to Leviathan. Drilling began at the Leviathan-7 development and production well, and reached the planned depth of 2,900 meters below sea level. The Atwood Advantage rig subsequently moved to Leviathan-5 and is expected to drill to a final depth of 5,200 meters below sea level. Finally, the rig will return to Leviathan-7 well to drill further to 5,100 meters below sea level. Financing Highlights: On May 12, 2017, all of the preconditions enabling initial withdrawal under the financing agreement were fulfilled. The Partnerships subsequently withdrew the first tranche. These first funds shall be used, inter alia, for payment to the operator, as well as for the costs of the financing. Delek Group's Gas Partnerships' Merger. On May 17, 2017, all of the preconditions and necessary approvals were obtained, and the gas partnerships' subsidiaries were successfully merged, enabling a simpler structure for Delek Group. Avner ceased trading on May 18, 2017, and on May 21, 2017, Delek Drilling began trading as the new merged entity under the same name, Delek Drilling. East Mediterranean E&P Summary. Net income from the sector for the first quarter of 2017 was NIS 119 million, an increase compared to a net income of NIS 101 million last year. The growth was mainly due to the increase in the quantities of natural gas and condensate sold from the Tamar project in the quarter. Delek Group's strategy is to focus on the development of its core assets in the Eastern Mediterranean E&P and expand its activities in global E&P markets, with the intention of becoming a key international player in the energy industry with operational capabilities. Ithaca Energy, Inc: On March 14, 2017, Delek Group offered to buy the remainder of all Ithaca's share capital not already held (80%), at a price of CAD 1.95 per share, following an agreement signed between the Group and Ithaca for issuing a friendly takeover offer. The offer was accepted by the holders of 318,833,909 ordinary shares and the Company bought these shares for a total consideration of CAD 622 million  (NIS 1,710 million). Following this purchase, Delek Group held 500,699,334 ordinary shares in Ithaca, accounting for 94.2% of its ordinary share capital. On May 12, 2017, Delek Group announced that it plans to perform a forced purchase of Ithaca's remaining ordinary shares not held by the Company, at the offer price (CAD 1.95 per share) for a total consideration of CAD 48 million (NIS 130 million). The forced purchase is expected to be completed by the end of June 2017, and Ithaca's shares will be delisted from the Toronto stock exchange and the AIM exchange in London. As of the end of the quarter, Delek Group held 19.7% of the share capital of Ithaca Energy. For the first quarter of 2017, Ithaca's results are presented based on the equity method and contributed NIS 8 million to the Company's income statement. By the end of the second quarter of 2017, the Group is expected to hold 100% of Ithaca, and its results will be fully consolidated into Delek Group's income statement. Due to this purchase, the Group is expected to recognise a profit of NIS 150 million. Operational Highlights: The start-up of the Great Stella Area commenced production in mid-February 2017, producing at constrained rates to minimise gas flaring until processing systems are fully available. Ithaca's average full year 2017 production is anticipated to be in the range of 18,000 to 19,000 Boep/d, reflecting the expected schedule for the step-up in Stella production rates. Ithaca brings Delek Group significant international operational capabilities and firmly establishes the Company's operational arm. Together with Ithaca, Delek Group significantly increases its expected production for 2017 is indicated in the table below; Delek – the Israel Fuel Company Ltd. (fully held by Delek Group); net income for the quarter amounted to NIS 20 million compared with a net income of NIS 4 million in the same period in 2016. The increase was primarily due to a global increase in distillate prices and greater sales volumes. On August 21, 2016, the Group entered into a binding agreement with Yango Investments for the sale of all the Company's holdings (52.3%) in Phoenix Holdings Ltd. On February 16, 2017, the parties signed an amendment to the agreement, extending the period for meeting the stipulated pre-conditions until March 31, 2017. On April 5, 2017, the parties signed an amendment to the agreement, increasing the consideration to NIS 2,152 million. The deadline for completion has been set for June 4, 2017. After this date, each of the parties may inform the other party of its cancellation. On May 1, 2017, Yango informed the Company that it has signed an agreement for the acquisition of shares and cooperation with a company controlled by Yonel Cohen. Yango is expected to hold 50.1% of the share capital in The Phoenix at the end of the process and Yonel will hold 4% of the controlling shares. On May 28, 2017, the Board of Directors of Delek Group declared a cash dividend distribution for the first quarter of 2017 in the amount of approximately NIS 200 million (or NIS 16.6895 per share) to shareholders. The ex-date is on June 13, 2017 and the dividend will be paid on June 27, 2017. The Company will be hosting a conference call in English on Monday, May 29, 2017 at 3.30 PM (Israel Time), 8:30 AM (ET), 1:30 PM (UK). Management will also be available to answer investor questions. To participate, please call one of the following teleconferencing numbers: From the USA on:   1-888-668-9141 Delek Group is an independent E&P and the pioneering visionary behind the development of the East Med. With eight consecutive finds in the Levant Basin, Delek is leading the region's development into a major natural gas export hub. In addition, Delek has embarked on an international expansion with a focus on high-potential opportunities in the North Sea and North America. Delek Group is one of Israel's largest and most prominent companies with a consistent track record of growth. Its shares are traded on the Tel Aviv Stock Exchange (TASE: DLEKG) and are part of the TA 35 Index. For more information on Delek Group please visit www.delek-Group.com or email: investor@delek-Group.com Contact: Investors Dina Vince Head of Investor Relations Delek Group Ltd. Tel: +972-9-863-8444 investor@delek-Group.com   Media Nilly Richman Head of Communications Delek Group Ltd. Tel : +972-9-863-8444 media@delek-Group.com To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/delek-group-announces-consolidated-results-for-the-first-quarter-of-2017-300464997.html


Disaster recovery service provider Databarracks, has become a ‘Corporate Partner’ of the Business Continuity Institute (BCI), working with it to raise the profile of business continuity management (BCM) as a critical discipline for business resilience, amongst the SME community. Founded in 1994, the BCI has established itself as the leading organisation for BC professionals worldwide, supporting over 8,000 members in more than 100 countries and working with an estimated 3,000 organisations in private, public and third sectors. BCI members receive access to a wealth of resources and industry knowledge, centered around developing and maintaining professional competency in BC. A growing number of organisations are taking proactive steps to improve their business resilience. Evidence from this can be seen from Databarracks’ latest annual Data Health Check survey, which reveals that over the past eight years the volume of organisations adopting BC plans has increased from 37 per cent to 67 per cent. As a ‘Corporate Partner’, Databarracks will aim to help grow this figure further by working with the BCI to provide education and awareness of BCM best practice, notably amongst the SME community. Peter Groucutt, managing director of Databarracks commented: “The small and medium sized businesses in the UK that we work with will rarely have their own dedicated BC professionals. Our aim is to take the best-practice, expertise and knowledge and make it applicable and usable for our customers. Often we see the distinction between BC and IT disaster recovery (DR) are blurred for smaller businesses. We have been helping our customers with IT DR, but we want to go beyond IT to help improve overall business resilience. We are training all of our customer facing staff in the fundamentals of business continuity and now that we are a Corporate Partner of the BCI, we want to work with the institute to help raise the profile of BCM and improve resilience. David Thorp, Executive Director of the BCI added to this and welcomed Databarracks to the BCI: “It is a pleasure to welcome Databarracks as a Corporate Partner of the BCI and we look forward to working with them to help advance the industry. Databarracks bring a unique insight into the world of disaster recovery. Additionally, their drive and determination to help organisations become more secure and more resilient is a goal we both share. With our own Horizon Scan Report identifying just how great a threat the cyber landscape can pose to all organisations, it is essential that organisations work together to help combat this threat and improve resiliency.” About the Business Continuity Institute Founded in 1994 with the aim of promoting a more resilient world, the Business Continuity Institute (BCI) has established itself as the world’s leading Institute for business continuity and resilience. The BCI has become the membership and certifying organization of choice for business continuity and resilience professionals globally with over 8,000 members in more than 100 countries, working in an estimated 3,000 organizations in the private, public and third sectors. The vast experience of the Institute’s broad membership and partner network is built into its world class education, continuing professional development and networking activities. Every year, more than 1,500 people choose BCI training, with options ranging from short awareness raising tools to a full academic qualification, available online and in a classroom. The Institute stands for excellence in the resilience profession and its globally recognised Certified grades provide assurance of technical and professional competency. The BCI offers a wide range of resources for professionals seeking to raise their organization’s level of resilience, and its extensive thought leadership and research programme helps drive the industry forward. With approximately 120 Partners worldwide, the BCI Partnership offers organizations the opportunity to work with the BCI in promoting best practice in business continuity and resilience. For more information, please see: http://www.thebci.org About Databarracks: Databarracks provides ultra-secure, award winning Disaster Recovery, Backup and Infrastructure services from UK-based, ex-military data centres. Databarracks is certified by the Cloud Industry Forum, ISO 27001 certified for Information Security and has been named as a “Niche Player” in Gartner’s 2016 Magic Quadrant for DRaaS for the second year in a row. For more information, please see: http://www.databarracks.com


News Article | April 21, 2017
Site: www.techrepublic.com

An infographic demonstrating the importance of adding business continuity management (BCM) capabilities to cybersecurity protection, with statistics illustrating facts such as the cost of a data breach, the projected scope of the cybersecurity problem and the benefits of using BCM.


News Article | April 26, 2017
Site: www.prnewswire.com

In der im April 2017 in der Fachzeitschrift Scientific Reports von Shusuke Toden, Ph.D., et alia (Baylor University, Dallas, Texas) veröffentlichten Studie wird die entzündungshemmende Wirkung beziehungsweise Bioaktivität von zwei Produkten mit verschiedener Bioverfügbarkeit und Zusammensetzung (normaler Kurkuma und BCM-95) anhand eines anerkannten, auferlegten Kolitis-Tiermodells verglichen. BCM-95 besteht aus reinen Curcuminoiden und ätherischen Kurkumaölen mit einem spezifischen Gehalt an Turmeronen. Die Ergebnisse der Studie zeigen, dass ätherische Öle mit Curcuminoiden dem normalen Kurkuma gegenüber überlegen dabei waren, die Krankheitsaktivität und die Belastung durch Entzündungen im Modell zu reduzieren. Zudem war die größere therapeutische Wirksamkeit von BCM-95 gegenüber normalen Kurkuma bei Kolitis neben der Bioverfügbarkeit anderen Eigenschaften zuzuschreiben, wie den Synergieeffekten zwischen Bestandteilen in dieser markengeschützten Zusammensetzung. BCM-95 ist eine proprietäre Rezeptur bestehend aus Arjunanatural-Extrakten zusammen im Joint Venture mit Dolcas Biotech LLC., ohne zusätzliche synthetische Zusatzstoffe. In BCM-95 bildet diese einzigartige Synergie ein 95 % reines, mit Bioaktivität verbessertes Kurkuma, um ein hocheffektives Kurkumaextrakt mit überlegener Bioverfügbarkeit zu schaffen. Es wurde umfangreich in verschiedenen klinischen Studien an Universitäten in den USA, Japan, Australien und Indien erforscht und mit 13 internationalen Patenten ausgezeichnet.


News Article | April 17, 2017
Site: co.newswire.com

BCM One, a leading technology solutions provider, announced a new cloud practice and solution set called Intelligent Cloud.  Intelligent Cloud provides a service portfolio that gives its clients the capability to monitor, analyze, model and orchestrate their cloud consumption. BCM One Intelligent Cloud Solutions are designed to offer businesses advanced analytics to help clients anticipate revenue and profit impacting change.  Intelligent Cloud is powered by a bundle of services including Cloud Optimization – helping companies realize their cloud usage and expenses from Azure and AWS, Predictive Analytics and Modeling from Microsoft Power BI, Network Infrastructure and Connectivity via Express Route and SD WAN -- including network analysis and optimization and Storage via Microsoft Data Lake, as an example.  In addition, the Intelligent Cloud provides supplementary services such as virtual desktop services, Office 365 and Skype for Business.  This service portfolio is all supported by BCM One’s Professional Services and a team of certified cloud architects and network engineers.  This team helps businesses migrate, manage and monitor the Intelligent Cloud. “We’re very excited to announce the next evolution in cloud technology, that simply stated, empowers business decision makers to realize tangible results of cloud solutions,” stated Rick Rios, Executive Director of the BCM One Intelligent Cloud Practice.  “Our cloud architects can harvest the insight of past trends to create predictive models that will allow our clients to minimize business risk.”  “BCM One started offering cloud solutions to our clients over four years ago, and we are very excited to bring cloud technology to an advanced level which seeks to compliment costs savings and build governance around the consumption of cloud within organizations,” added John Cunningham, Founder & Co-CEO of BCM One. To learn more details on BCM One’s New Intelligent Cloud Practice and Solutions, meet BCM One at their Technology Lounge at Channel Partners Spring in Room Islander H on Tuesday, April 11 from 1:00 – 4:00PM and on Wednesday, April 12 from 11:00 AM – 3:00PM.  Rick Rios will be on-hand to discuss this exciting new Cloud Practice and the unique value that it can bring to channel partners and their clients. Founded and headquartered in New York City in 1992, BCM One provides a single source for truly integrated technology solutions that help advance a company's business objectives. Through partnerships with over 50 leading technology suppliers, BCM One offers managed solutions for organizations including unified communications, cloud solutions, telecom expense optimization and connectivity solutions. Companies engage with BCM One for the planning, network design, deployment and/or management of their technology solutions. For more information about BCM One, visit www.bcmone.com and follow us on Twitter and LinkedIn.


News Article | April 25, 2017
Site: www.eurekalert.org

Neuroscientists have, for the first time, shown that gut bacteria "speak" to the brain to control food choices in animals. In a study publishing April 25 in the Open Access journal PLOS Biology, researchers identified two species of bacteria that have an impact on animal dietary decisions. The investigation was led by Carlos Ribeiro, and colleagues from the Champalimaud Centre for the Unknown in Lisbon, Portugal and Monash University, Australia. There's no question that nutrients and the microbiome, the community of bacteria that resides in the gut, impact health. For instance, diseases like obesity have been associated with the composition of the diet and the microbiome. However, the notion that microbes might also be able to control behavior seems a big conceptual leap. Yet that's what the new study shows. Experiments conducted using the fruit fly Drosophila melanogaster, a model organism allowed the scientists to dissect the complex interaction of diet and microbes and its effect on food preference. The scientists initially showed that flies deprived of amino acids showed decreased fertility and increased preference for protein-rich food. Indeed, the team found that the removal of any single essential amino acid was sufficient to increase the flies' appetite for protein-rich food. Furthermore, the scientists tested the impact on food choices of five different species of bacteria that are naturally present in the guts of fruit flies in the wild. The results exceeded the scientists' expectations: two specific bacterial species could abolish the increased appetite for protein in flies that were fed food lacking essential amino acids. "With the right microbiome, fruit flies are able to face these unfavorable nutritional situations," says Santos. "In the fruit fly, there are five main bacterial species; in humans there are hundreds," adds co-author Patrícia Francisco. This highlights the importance of using simple animal models to gain insights into factors that may be crucial for human health. How could the bacteria act on the brain to alter appetite? "Our first hypothesis was that these bacteria might be providing the flies with the missing essential amino acids," Santos explains. However, the experiments did not support this hypothesis. Instead, the gut bacteria "seem to induce some metabolic change that acts directly on the brain and the body, which mimics a state of protein satiety," Santos says. In sum, this study shows not only that gut bacteria act on the brain to alter what animals want to eat, but also that they might do so by using a new, unknown mechanism. In your coverage please use this URL to provide access to the freely available article in PLOS Biology: https:/ Citation: Leitão-Gonçalves R, Carvalho-Santos Z, Francisco AP, Fioreze GT, Anjos M, Baltazar C, et al. (2017) Commensal bacteria and essential amino acids control food choice behavior and reproduction. PLoS Biol 15(4): e2000862. doi:10.1371/journal.pbio.2000862 Funding: Portuguese Foundation for Science and Technology (FCT) (grant number postdoctoral fellowship SFRH/BPD/78947/2011). Received by RLG. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript; Portuguese Foundation for Science and Technology (FCT) (grant number PTDC/BIA-BCM/118684/2010). Received by CR. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript; Human Frontier Science Program (grant number RGP0022/2012). Received by CR. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript; EUROPEAN COMMISSION - MARIE CURIE ACTIONS (grant number FLiACT - Grant agreement no.: 289941). Received by CR. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript; Ciência sem Fronteiras program of the CNPq (grant number 200207/2012-1). Received by GTF. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript; Royal Society (grant number UF100158). Received by MDWP. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript; BIAL Foundation (grant number 283/14). Received by CR. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript; EMBO (grant number ALTF 1602-2011). Received by RLG. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript; Biotechnology and Biological Sciences Research Council (grant number BB/I011544/1). Received by MDWP. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript; Champalimaud Foundation. Received by CR. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript; Australian Research Council (grant number Australian Research Council Future Fellow - FT150100237). Received by MDWP. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript; Portuguese Foundation for Science and Technology (FCT) (grant number postdoctoral fellowship SFRH/BPD/76201/2011). Received by ZCS. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript; Portuguese Foundation for Science and Technology (FCT) (grant number postdoctoral fellowship SFRH/BPD/79325/2011 ). Received by PMI. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript; Kavli Foundation. Received by CR. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Competing Interests: I have read the journal's policy and the authors of this manuscript have the following competing interests. PMI has a commercial interest in the flyPAD open-source technology.


News Article | April 25, 2017
Site: www.prnewswire.com

The study, published April, 2017, in the journal Scientific Reports, by Shusuke Toden, Ph.D., et alia, of Baylor University, Dallas, Texas, compared the anti-inflammatory efficacy, or bioactivity of two products of differing bioavailability and composition (standard curcumin and BCM-95) in a well-recognized, imposed animal model of colitis. BCM-95 composed of pure curcuminoids and essential oils from turmeric with a specific content of turmerones. The study's results demonstrated that the essential oil with curcuminoids was significantly more superior to standard curcumin in reducing the disease activity and inflammatory burden in the model. Moreover, the greater therapeutic efficiency of BCM-95 over standard curcumin in colitis was attributable to properties beyond enhanced bioavailability, including that of synergism between ingredients in this branded composition. "For the first time, the enhanced bioactivity of BCM-95 as a result of synergism has been confirmed," says Benny Antony, PhD, Joint Managing Director for Arjuna. "This new finding provides our customers an added value for promoting their BCM-95-based formulations in an increasingly crowded curcumin market." BCM-95 is a proprietary formulation of Arjunanatural extracts in joint venture with Dolcas Biotech LLC. without any synthetic additives. In BCM-95, this unique synergy forms a 95%-pure, bioactivity enhanced curcumin to create a highly effective turmeric extract with superior bioavailability. It has been extensively researched in multiple clinical studies by universities throughout the US, Japan, Australia, and India, and has been awarded 13 international patents. BCM-95 is available in the US market through Dolcas Biotech LLC. The two companies have campaigned around the notion of synergism in turmeric constituents since the ingredient's market debut nearly 15 years ago. Synergism has been previously confirmed in the case of enhancing bioavailability. "BCM-95 is backed by dozens of clinical research studies that show numerous health benefits," notes P.J. Kunjachan, Chairman & Managing Director for Arjuna. The therapeutic benefits of turmeric can be attained at its best by combining curcumin with turmerone, an active compound derived from essential oil of turmeric. Arjuna has full supervision of BCM-95's supply chain, from farm to finished supplement, to provide a pure, clean and safe product. DolCas recently received self-affirmed GRAS status for BCM-95 turmeric extract following a comprehensive review by a panel of qualified experts. The pure, high-potency ingredient is available for use in food and supplements. For further information, please contact:


News Article | April 25, 2017
Site: www.prnewswire.co.uk

The study, published April, 2017, in the journal Scientific Reports, by Shusuke Toden, Ph.D., et alia, of Baylor University, Dallas, Texas, compared the anti-inflammatory efficacy, or bioactivity of two products of differing bioavailability and composition (standard curcumin and BCM-95) in a well-recognized, imposed animal model of colitis. BCM-95 composed of pure curcuminoids and essential oils from turmeric with a specific content of turmerones. The study's results demonstrated that the essential oil with curcuminoids was significantly more superior to standard curcumin in reducing the disease activity and inflammatory burden in the model. Moreover, the greater therapeutic efficiency of BCM-95 over standard curcumin in colitis was attributable to properties beyond enhanced bioavailability, including that of synergism between ingredients in this branded composition. "For the first time, the enhanced bioactivity of BCM-95 as a result of synergism has been confirmed," says Benny Antony, PhD, Joint Managing Director for Arjuna. "This new finding provides our customers an added value for promoting their BCM-95-based formulations in an increasingly crowded curcumin market." BCM-95 is a proprietary formulation of Arjunanatural extracts in joint venture with Dolcas Biotech LLC. without any synthetic additives. In BCM-95, this unique synergy forms a 95%-pure, bioactivity enhanced curcumin to create a highly effective turmeric extract with superior bioavailability. It has been extensively researched in multiple clinical studies by universities throughout the US, Japan, Australia, and India, and has been awarded 13 international patents. BCM-95 is available in the US market through Dolcas Biotech LLC. The two companies have campaigned around the notion of synergism in turmeric constituents since the ingredient's market debut nearly 15 years ago. Synergism has been previously confirmed in the case of enhancing bioavailability. "BCM-95 is backed by dozens of clinical research studies that show numerous health benefits," notes P.J. Kunjachan, Chairman & Managing Director for Arjuna. The therapeutic benefits of turmeric can be attained at its best by combining curcumin with turmerone, an active compound derived from essential oil of turmeric. Arjuna has full supervision of BCM-95's supply chain, from farm to finished supplement, to provide a pure, clean and safe product. DolCas recently received self-affirmed GRAS status for BCM-95 turmeric extract following a comprehensive review by a panel of qualified experts. The pure, high-potency ingredient is available for use in food and supplements. For further information, please contact:

Loading BCM collaborators
Loading BCM collaborators